The aim of this partnership is to leveraging RetinAI’s Discovery platform and AI tools to help Eyestem advance in its mission of treatment for geographic atrophy with its cell therapy, Eyecyte-RPE™.
Jogin Desai, Founder and CEO of Eyestem, said in a statement, “This collaboration with RetinAI marks a significant milestone in our journey. Their sophisticated AI tools and the RetinAI Discovery® platform integrate perfectly with our vision, potentially shortening the timelines for our clinical trials and enhancing the accuracy of our analyses. ”
Carlos Ciller, CEO of RetinAI, said in a statement, “We are excited to partner with Eyestem. Our AI-driven Discovery® platform is poised to significantly accelerate research and provide enhanced insights into disease progression and outcomes. Together, we’re confident that this synergy will not only enrich insights in the development of novel treatments but also manifest in delivering life-altering solutions faster to individuals affected by retinal diseases globally.”
Geographic atrophy, a late-stage form of dry age-related macular degeneration (AMD), is a significant health concern worldwide. Currently, dry AMD affects 200 million individuals globally, contributing to irreversible vision loss. Compounded by an aging population, the prevalence of this serious eye disease is escalating at an alarming rate.
Eyestem is preparing to initiate its Phase I/IIa clinical trials for Eyecyte-RPE™. This multi-centre, dose escalation, and expansion trial aims to assess Eyecyte-RPE™’s safety and efficacy for geographic atrophy. This trial will benefit from RetinAI’s Discovery® platform, which will centralise data management and image analysis for the study. Moreover, RetinAI’s advanced segmentation model will be leveraged for the identification and quantification of retinal biomarkers in geographic atrophy. This automated analysis will provide real-time insights on clinical endpoints, speeding up critical decision-making.
